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Abbreviations 
 
ASD - atrial septal defect  
VSD - ventricular septal defect  
PAPVC - partial anomalous pulmonary venous connection 
CHD - coronary heart disease (significant stenosis or prior myocardial infarction) 
LA - left atrium, RA - right atrium  
EDD - end-diastolic left ventricular diameter  
ESD – end-systolic left ventricular diameter  
EF - left ventricular ejection fraction 
PPI - post-pacing interval after entrainment  
TCL - tachycardia cycle length 
AF – atrial fibrillation  
AFL –atrial flutter  
CTId – cavostricuspid isthmus dependent  
PVI – pulmonary vein isolation 
AAD - antiarrhythmic drug  
ACE - angiotensin-converting enzyme 
BSA - body surface area  
COPD - chronic obstructive pulmonary disease  
ICD - implantable cardioverter defibrillator  
LVEF - left ventricular ejection fraction. 
2C - 2-chamber view 
4C - 4-chamber view  
E - early diastolic peak transmitral flow velocity 
E’ lateral, septal, avg - annular velocity at lateral, septal side, and the average of them   
TDI - tissue Doppler imaging 
PWD – pulsed-wave Doppler 
LAA - LA area  
LAV - LA volume  
LAVi - LA volume indexed to body surface area   
LAVmax - LA maximum volume  
LAVmin - LA minimum volume  
PVD - pulmonary vein diastolic flow velocity  
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PVS - pulmonary vein systolic flow velocity  
PVSD - ratio of PVS and PVD 
CM – cardiomyopathy 
CI - confidence interval  
DCCV - direct current cardioversion  
OR - Odds ratio 
 
4 
 
Introduction 
 
Treatment of atrial tachycardias has changed a lot in the last decade; catheter ablation has 
emerged as the curative therapy. In order to achieve the better outcome, clinical 
arrhythmologists are paying more attention to the anatomy and function of the atrial structure. 
Being familiar with atrial anatomy, structure and function is particularly important to treat 
patients with atrial tachycardias. Out of these atrial tachycardias, atrial ﬁbrillation (AF) is the 
most common arrhythmia in the clinical practice and is associated with several important 
adverse clinical outcomes, including impairment of quality of life, embolic events and 
congestive heart failure.1  Atrial fibrillation itself produces changes in atrial function and 
structure which could play a role in the development of these clinical consequences. 
According to experimental studies, episodes of AF generate even longer AF episodes and 
continuous atrial remodeling.2 This remodeling manifests in several levels such as electrical, 
structural and contractile remodeling. All of these components can create a vicious circle. 
After the arrhythmia has been triggered, it affects the ion currents and ion channels at first and 
creates electrical remodeling. Contractile remodeling refers to a reduction in atrial contraction 
with an increased wall tension and finally atrial dilatation which is the hallmark of 
remodeling. The existence of atrial fibrillation not only changes the electrical activity of the 
atria, but it has a strong influence on the ultrastructure of the chamber.  
Pulmonary vein isolation (PVI) using radiofrequency catheter ablation (RFA) is an important 
and effective therapeutic option for AF.3 Since Haissaguere’s discovery, the pulmonary vein 
isolation has become a well-established method for the treatment of either paroxysmal or 
persistent atrial fibrillation.4 Several technical improvements and advances have been 
introduced in the last two decade, but AF recurrences are common after the procedures, a 
signiﬁcant number of patients require repeated attempts. The recurrence rate of AF after 
catheter ablation is reported to be as high as 15-50% depending on the ablation strategy and 
the AF type.3,5 Most recurrences occur in the first 6 months after ablation, but even after 1 
year, an annual additional recurrence rate of 5–9% has been described.6,7 Awareness of these 
results and careful patient selection are really important to target the most appropriate 
population with the previously mentioned approach.  
Left atrial (LA) dimension, left ventricular (LV) ejection fraction and valvulopathies 
can influence AF recurrences. The left atrium has a significant functional role in cardiac 
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performance by varying left ventricular filling with its reservoir, conduit and contractile 
functions.8 With the noncompliance of the LV, LA pressure rises to maintain adequate LV 
filling and the subsequent atrial wall tension leads to chamber dilatation, stretching of the 
atrial myocardium and longstanding elevation of afterload, which finally causes remodeling 
of the LA.9 Left atrial volume increases with the progression of diastolic dysfunction, 
consequently the LA volume influences the LV filling pressures over time.10 Despite the 
numerous data in the literature, the association between clinical and diastolic parameters and 
recurrence after catheter ablation in atrial fibrillation is not fully described. In last few years, 
many new echocardiographic parameters have been described to characterize the diastolic 
function in patients with AF. Patients with AF recurrence had signiﬁcantly larger LA size, 
increased early diastolic transmitral ﬂow velocity (E) and increased E/E’ (ratio of early 
diastolic peak transmitral inﬂow to early diastolic peak mitral annular velocity).11,12 Indexed 
LA volume (LAV) was shown to be strongly associated with AF recurrence after catheter 
ablation in a cohort of patients with paroxysmal and persistent AF.13,14 Among the tissue 
Doppler imaging (TDI) parameters, the E/E’ is the key parameter in the estimation of the 
degree of diastolic dysfunction and this parameter was evaluated for AF recurrence after 
electrical cardioversion15 and catheter ablation.11 Based on these results, there is no single 
echo parameter which can be able to clearly predict AF occurrence and identify patients who 
will benefit from catheter ablation. 
Atrial flutter often coexists with atrial fibrillation. It can produce atrial electrical 
remodeling similarly as AF16 and probably is the most common atrial arrhythmia in patients 
who undergo open heart surgery. Several types of atrial flutters may develop in this very 
special subgroup of patients and the strategy of treatment is different compared to patients 
with typical flutter without heart surgery. Heart surgery for acquired valvular problems or 
ischemic heart disease involves incisions applied to the right and/or left atrium either for 
establishing extracorporeal circulation or for approaching the intracardiac structures (coronary 
sinus, interatrial or interventricular septum, atrioventricular valves, etc.).17 These atriotomies 
create an ideal substrate for atrial tachycardias (AT) together with structural and 
hemodynamic changes resulting from the underlying heart disease. These two factors have 
been thought to play a major role in the development of atrial tachycardia (AT) months or 
even years after surgery.18-22 Detailed knowledge of the underlying anatomy, surgical 
techniques and incisions are critical in understanding the mechanism of the subsequent 
arrhythmia. Besides the most common cavotricuspid-isthmus (CTI)-dependent atrial flutter 
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(AFL), atypical AFLs are also not uncommon in these population of patients.23,24 AT 
mechanisms can be different depending on the underlying heart disease, the type of the 
operation, and specifically the type of atrial incision applied during the surgery. Due to the 
complexity of multiple AFL circuits, an empirical approach has been suggested in sinus 
rhythm in patients with previous heart surgery and coexistent atrial incisions. 18-20,25  
Aims 
 
1. According to the observations associated with AF and diastolic dysfunction, we sought 
to evaluate atrial diastolic function parameters including two-dimensional (2D), 
pulsed-wave Doppler (PWD) and TDI parameters, and the directly measured left atrial 
pressure (LAP) values for associations with AF recurrence after RFA in a large cohort 
of patients with persistent and longstanding persistent AF. 
2. We sought to perform a long-term follow-up study of patients with AF recurrence 
after catheter ablation to determine whether the time to recurrence of AF influenced 
AF characteristics, response to therapy and clinical outcome. 
3. We sought to establish an association between organic heart disease, atrial incisions, 
and the mechanism of AT developing late after open heart surgery in a routinely 
encountered patient population with acquired or simple congenital heart disease. 
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Methods 1.  
 
Study Population 
The study protocol was approved by the Institutional Review Board at our institution with 
waiver of consent for retrospective review of medical records. There were 493 patients with 
drug refractory persistent and longstanding persistent AF who underwent PVI by RFA at the 
Hospital of the University of Pennsylvania between April 2009 and April 2011. The patients 
were excluded from analysis if they had previous catheter ablation (251 patients), a history of 
open heart surgery (17 patients), moderate or severe mitral regurgitation (14 patients), 
reduced LV ejection fraction (EF) (< 50%, 30 patients), mitral annular calciﬁcation (ﬁve 
patients), pacemaker dependency (four patients), no LA pressure registration (25 patients), 
were in AF the following day after catheter ablation (seven patients), and less than 6 months 
follow-up (21 patients). Persistent AF was deﬁned as continuous AF for greater than 7 days or 
cardioversion after 48 hours of continuous AF. Longstanding persistent AF was deﬁned as 
continuous AF for greater than 12 months.26 Clinical data were obtained from medical 
records. 
 
Echocardiography 
All patients underwent routine clinical transthoracic echocardiogram (TTE) examinations 
including M-mode, 2D, PWD and TDI on the ﬁrst postprocedural day following PVI. All 
studies were analyzed in a blinded fashion on dedicated workstations (ProSolv 
CardioVascular Client version 4.0.4) by a single reader. Left atrial diameter was obtained in 
the parasternal long axis view. Left atrial area (LAA) and left atrial length were measured in 
the apical 4-chamber (4C) view and apical 2-chamber (2C) view. LAV was derived using the 
biplane area-length method. Both LAA and LAV were measured at LV end-systole (LA 
maximum volume, LAVmax; LA maximum area, LAAmax) and at LV end-diastole (LA 
minimum volume, LAVmin; LA minimum area, LAAmin). LAV index (LAVi) was 
calculated based on the body surface area. Mitral inﬂow measurements using PWD included 
peak early diastolic velocity (E) and deceleration time (DT) of early diastolic velocity. Late 
diastolic velocity (A) is not obtained due to generally diminutive velocities 1 day 
postablation. Pulmonary venous ﬂows using PWD were characterized by peak systolic 
velocity (PVS), peak diastolic velocity (PVD), and the ratio of PVS to PVD (PVSD). TDI 
obtained from the 4C view included early velocities from the septal and lateral mitral annulus 
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(E’septal and E’lateral, respectively). The ratio of early diastolic transmitral ﬂow velocity to 
annular motion velocity was calculated for both lateral and septal annular sites (E/E’lateral 
and E/E’septal, respectively) and was also calculated for the average between the two sites 
(E/E’average). 
 
Catheter Ablation and left atrial pressure (LAP) recordings 
PVI was performed per routine at our institution as previously described.27,28 Brieﬂy, 
multipolar catheters were placed in the coronary sinus and posterior right atrium (RA) and a 
diagnostic intracardiac ultrasound catheter was advanced to the RA. Two transseptal 
punctures were performed through which the ablation and circular mapping catheters were 
advanced into the LA. A bolus of unfractionated heparin was administered prior to the ﬁrst 
transseptal puncture and infusion was titrated to maintain activated clotting time 
of > 350 seconds for the duration of the procedure. Immediately after the transseptal access, 
the LA pressure was transduced through the transseptal needle. LA x-wave pressure nadir, LA 
peak v-wave pressure, and mean LA pressure were recorded using an electrophysiologic 
recording system (Prucka-GE, Houston, TX, USA). The ablation endpoints were absence of 
PV potential recordings of the circular mapping catheter, which deﬁned entrance block; 
failure to capture the LA when pacing from all bipoles of the circular mapping catheter 
(output 10 mA, pulse width 2 ms), deﬁned exit block29; and no AF with incremental infusion 
of up to 20 μg/min of isoproterenol. Additional ablation procedures were performed as 
clinically appropriate by the electrophysiologists. 
 
Routine Follow-Up 
All patients underwent a TTE the day after the procedure. Patients were typically restarted on 
previous antiarrhythmic drugs prior to discharge and continued during follow-up at the 
discretion of the clinician. Patients had outpatient visits at 6–10 weeks and 6 months, and the 
majority of patients had visits at 1 year from the date of the ablation procedure. Patients 
routinely underwent a 4-week period of transtelephonic monitoring immediately after ablation 
and at least once again at 3–12 months to assess for asymptomatic AF recurrence. At each 
outpatient visit, patient symptoms were assessed and a 12-lead electrocardiogram (ECG) was 
recorded. Beyond the 1-year period, the patients were either seen at our institution or by their 
local cardiologist based on their preferences but followed with telephone calls from our 
center.  
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Statistical Analysis 
Statistical analyses were performed using STATA software (version 10, StataCorp, College 
Station, TX, USA). Continuous variables were expressed as mean ± standard deviation and 
categorical variables were expressed as percentages. Comparison of data between the two 
groups with and without recurrence was performed using a two-tailed, unpaired Student’s t-
test for continuous variables and χ2 test for the categorical variables. Logistic regression 
analysis was used to identify univariate and multivariable parameters of AF recurrence. Note 
that P values of ≤ 0.05 were considered statistically signiﬁcant. 
  
Reproducibility 
Fifteen randomly selected TTE studies were reviewed by another independent blinded 
observer to assess interobserver variability. The same 15 studies were reinterpreted by the 
original reader in a blinded fashion 3 months after the initial reading to assess intraobserver 
variability. 
 
Methods 2. 
 
Study population 
We identified patients who (1) underwent first catheter ablation for AF at the Hospital of the 
University of Pennsylvania between 2004 and 2008, (2) had recurrent AF after ablation, and 
(3) had a minimum of 18-month follow-up after recurrence. Patients were divided into an 
early (E) recurrence group, with recurrences occurring 3–6 months of ablation, a late (L) 
group, with recurrences occurring between 6 and 12 months, and a very late (VL) group, with 
recurrences occurring > 1 year after ablation. 
 
Ablation strategy and routine follow-up 
PVI and routine follow-up was performed as previously described.27-31 
 
Definitions 
Because AF that occurs very early after ablation may be transient, AF recurrences occurring 
within the first 3 months of ablation were excluded. In contrast, documented episodes of AF 
or any organized atrial arrhythmia lasting > 30 seconds after the 3-month blanking period 
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were counted as AF recurrences. In order to facilitate analysis, the arrhythmia burden after the 
initial recurrence was dichotomized as being rare only if during every 6-month follow-up 
window, no AF or ≤ 2 AF episodes occurred and ≤ 1 direct current cardioversion (DCCV) 
was performed. Patients were considered drug responders if after initiating new drug therapy 
because of AF recurrence the patient had no symptomatic AF with at least 6 months of 
additional clinical follow-up and at least one > 2-week TTM showing no recurrence. After a 
repeat AF ablation procedure, AF control was defined as AF free or rare AF episodes in each 
year of follow-up (12-month minimum) with at least 1 extended period of transtelephonic 
ECG monitoring. For those patients with rare episodes before repeat ablation, a more stringent 
definition of AF control was used after repeat ablation (no or only 1 episode of AF during the 
follow-up of at least 1 year). 
 
Statistical analysis 
Continuous variables are expressed as mean ± SD and categorical variables as number 
(percentages). The analysis of variance test was used to compare continuous variables across 
multiple groups. The χ2 test with Yates correction or Fisher exact test was used to analyze 
categorical variables. Multivariate logistic regression was utilized to identify predictors of 
favorable clinical outcomes after the initial recurrence. Variables included in Table 8 in 
addition to recurrences during the blanking period, DCCV during the blanking period, on 
AADs at the time of recurrence, and rare episodes after the blanking period were subjected to 
univariate screening. Variables showing marginal associations with favorable outcome 
(P < 0.10) were assessed in multivariate models. A 2-tailed P value of ≤ 0.05 was considered 
statistically significant. All statistical analyses were performed by using SPSS version 16.0 
(SPSS Inc, Chicago, IL). 
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Methods 3. 
 
Study population 
Consecutive patients undergoing electrophysiology study for documented AT at least 3 
months after open heart surgery for acquired or simple congenital heart disease were enrolled. 
Patients after complex corrective surgery (Senning, Mustard or Fontan procedure) were not 
included. Patients undergoing empirical CTI ablation (surface ECG documentation of typical 
flutter, ablation during sinus rhythm), non-inducible tachycardia or with previous surgical or 
catheter based ablation were excluded. Altogether one hundred patients were enrolled, clinical 
characteristics are summarized in Table 1.  
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Characteristics (N=100)   
Mean age (range), years 64 (23–89) 
Male/female  61/39 
Months since surgery   
 Median  60 
 Min–max 3–274 
Congenital heart disease   
 ASD  13 
 VSD  2 
 Ebstein 2 
 Pulm. stenosis 1 
 Fallot 2 
 PAPVC 2 
Acquired heart disease   
 CHD 31 
 Valvular  83 
 Myxoma 4 
Hypertension  62 
Diabetes  21 
LA diameter (mm)  52±9 
EDD (mm)  56±9 
ESD (mm)  39±10 
EF (%)  56±14 
 
Table 1. Clinical caracteristics of patients 
ASD: atrial septal defect, VSD: ventricular septal defect, PAPVC: partial anomalous 
pulmonary venous connection, CHD: coronary heart disease (significant stenosis or prior 
myocardial infarction), valvular heart disease moderate or greater regurgitation or significant 
stenosis, LA: left atrium, EDD: end-diastolic left ventricular diameter, ESD: endsystolic left 
ventricular diameter, EF: left ventricular ejection fraction 
 
Surgical technique 
Surgical procedures were grouped according to the incisions applied to the atria. In some 
cases, only a right atrial (RA) incision was placed: either for venous cannulation for 
cardiopulmonary bypass via a small incision on the RA appendage or a long incision on the 
RA free wall for the placement and fixation of a cardioplegic cannula inside the coronary 
sinus (open technique for retrograde cardioplegia) or to perform surgery at the right side of 
the heart. Venous cannulas for cardiopulmonary bypass in the latter cases were placed 
through incisions on the superior caval vein and the inferior vena cava-RA junction (bicaval 
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cannulation). In some patients, both RA and left atrial (LA) incisions were placed: The RA 
free wall atriotomy was prolonged superiorly and onto the interatrial septum to access the left 
atrium (transseptal LA atriotomy). The remaining patients had only LA operation using direct 
LA atriotomy (in the interatrial groove) along with bicaval cannulation (Fig. 1, Table 2). 
 
Figure 1. Schematic drawing of the different atrial incisions applied: 1 right atrial appendage 
cannulation, 2 right atrial free wall atriotomy, 3 transseptal left atriotomy, 4 direct left 
atriotomy 
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Atrial incision  Operation  N 
RA appendage cannulation  CABG 9 
  Ao  7 
  CABG and Ao  3 
  Pu  1 
RA free wall atriotomy  Retrograde cardioplegia (CABG and/or Ao)  14 
  ASD  13 
  VSD 2 
  Tr 3 
Transseptal LA atriotomy Mi 20 
  Mi and CABG 8 
  Mi and Ao  5 
  Mi and Tr  4 
  LA myxoma 4 
Direct LA atriotomy  Mi 6 
  Mi and Ao  1 
 
Table 2. Surgical procedures, CABG coronary artery bypass graft, Ao aortic valve, Pu 
pulmonary valve, ASD atrial septal defect, VSD ventricular septal defect, Tr tricuspid valve, 
Mi mitral valve, RA right atrial, LA left atrial 
 
Electrophysiology study 
Patients were studied under light sedation using midazolam ± fentanyl. Multipolar catheters 
were introduced through the femoral ± the internal jugular or the subclavian vein. One 
catheter was positioned in the coronary sinus (CS) with the most proximal bipole at the 
ostium. Another catheter was placed in the RA around the tricuspid annulus, with the most 
distal electrode in the low RA. A steerable catheter was used for mapping and pacing from 
other locations. Radiofrequency ablation was carried out by an externally irrigated ablation 
catheter (NaviStar ThermoCool, Biosense WebsterInc., Diamond Bar, CA, USA or Therapy 
Cool Path, St. Jude Medical Inc., St. Paul, MN, USA). During sinus rhythm, atrial 
extrastimulation was carried out at two drive cycle lengths, using at least two extrastimuli. 
This was repeated after ablation of every tachycardia. Only sustained (> 30 s) tachycardias 
amenable for detailed mapping are included in this analysis. Non-sustained, 
irregular (> 30 ms cycle length variation) tachycardias, and those that terminated or 
transformed during mapping were excluded. Activation mapping during AT was 
accomplished by multielectrode recording and in cases of non-CTI-dependent AT, use of an 
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electroanatomic mapping system (CARTO™ XP, Biosense Webster Inc.). Entrainment 
pacing was performed with a cycle length (CL) 10–30 ms shorter than the tachycardia CL. 
The pacing site was considered to be in the reentrant circuit if the post-pacing interval, 
measured from the pacing stimulus to the first non-paced electrogram recorded by the pacing 
electrode, was less than 30 ms longer than the tachycardia CL. Atrial tachycardias were 
classified as macro-reentrant (flutter) if distant atrial sites were determined to be part of the 
reentry circuit, and continuous atrial activation was demonstrated by activation mapping. 
Focal ATs were defined by centrifugal activation from a discrete source. Atrial flutter (AFL) 
was classified as CTI-dependent if entrainment mapping determined the CTI to be part of the 
circuit and the flutter terminated during ablation at the CTI. If the above were not fulfilled, the 
AFL was labeled non-CTI-dependent and further classified as RA incisional tachycardia, if 
the RA free wall was part of the circuit based on entrainment, a RA scar was detected either 
as an electrically quiescent area or a line of double potentials, continuous activation was 
demonstrated around the scar and the flutter terminated during ablation between the scar and a 
barrier such as the inferior vena cava or the tricuspid ring (Fig. 2). A non-CTI-dependent AFL 
was defined as perimitral flutter if the mitral isthmus (between the left-sided pulmonary veins 
and the mitral annulus) proved to be in the circuit based on entrainment, activation proceeded 
around the mitral ring and the flutter terminated during ablation between the mitral annulus 
and another barrier (Fig. 3). In case of a roof-dependent LA flutter the activation proceeded 
around the left or right pulmonary veins (PVs) and/or an area of scar on the posterior LA wall, 
the LA roof proved to be in the circuit by entrainment and the flutter terminated during linear 
ablation between upper PVs or the mitral isthmus in case of peri-left PV AFL. Upper loop 
reentry was defined as a flutter circuit in the RA, around the ostium of the superior caval vein. 
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Figure 2. Electroanatomic activation map of the right atrium during incisional tachycardia 
after right lateral atriotomy. The atriotomy is marked by light blue dots, indicating double 
potentials (see inlets for examples of such potentials) and parallel dotted lines. Activation 
proceeds in the counterclockwise direction around the atriotomy. Dark blue dots mark the 
tricuspid valve (TV) 
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Figure 3. Perimitral macroreentry after direct left atriotomy. Activation proceeds in the 
clockwise direction around the mitral annulus and also through a reconnection in the 
atriotomy line. This latter path is not part of the circuit as indicated by entrainment pacing. 
The circuit uses a narrow isthmus between the scar and the mitral annulus, where a single 
radiofrequency pulse (dark red dot) terminated the tachycardia. Orange dots represent pacing 
sites, light blue dots mark double potentials, grey dots, electrically silent areas, and pink dots 
represent fragmented signals. Light red dots mark the mitral annulus. PPI post-pacing interval 
after entrainment, TCL tachycardia cycle length. 
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Statistical analysis 
Continuous variables are presented as mean ± SD and were compared using Student’s t test. 
Categorical variables are presented as frequencies. Comparisons of proportions were 
performed by the chi-square test. If more than one variable was significantly related to a 
specific AT mechanism multivariable analysis by logistic regression was performed. A P 
value < 0.05 was considered statistically significant. Statistical analyses were performed using 
SPSS software, version 13.0 (SPSS Inc., Chicago, IL, USA). 
 
Results 1. 
 
Baseline Clinical Characteristics  
Baseline patient characteristics are shown in Table 3. The patients’ mean age was 
61.3 ± 8.9 years (range 36–78 years). This group of patients was predominantly male and 
hypertensive. Seventy-seven percent of patients had persistent AF, whereas 23% had 
longstanding persistent AF. All patients had preserved LVEF (> 50%). 
 
Procedural Outcomes  
A total of 125 patients were included in the study. The mean follow-up time of the study 
population was 17.8 ± 7.7 months. After the ﬁrst PVI, success was achieved in 73 patients 
(58.4%). Twenty patients had a second PVI and 10 of these patients remained in sinus rhythm 
(SR) during follow-up. Three patients had a third PVI but all failed to maintain SR. At the end 
of the follow-up period, 83 patients remained in SR (66.4%) and 42 (33.6%) had AF 
recurrence.  
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Characteristics  Total (n = 125) 
Demographics and Comorbidities   
 Age (years)  61.3 ± 8.9 
 BSA (m2)  2.1 ± 0.3 
 Gender (% male)  81 
 Hypertension (%) 66 
 Diabetes mellitus (%)  15 
 Stroke (%)  9 
 LVEF (%)  60.7 ± 6.4 
 Coronary artery disease (%) 13 
 Pacemaker or ICD (%)  2 
 Asthma, COPD (%)  8 
 Obstructive sleep apnea (%) 25 
Atrial Fibrillation    
 Longstanding persistent (%) 23 
 Persistent (%) 77 
 Duration of AF (months)  12.7 ± 20.2 
Baseline Medications (%)   
 ACE inhibitor  26 
 Angiotensin receptor blocker  14 
 Diuretic  28 
 Inhaled β-agonist  2 
 β-blocker  42 
 AAD Class I  32 
 AAD Class III  68 
 AAD Class IV  23 
 Digoxin  16 
Mean Follow-Up Time (Months) 17.8 ± 7.7 
 
Table 3. Baseline Characteristics of Patients, AAD = antiarrhythmic drug; 
ACE = angiotensin-converting enzyme; AF = atrial fibrillation; BSA = body surface area; 
COPD = chronic obstructive pulmonary disease; ICD =implantable cardioverter defibrillator; 
LVEF = left ventricular ejection fraction. 
 
Clinical Parameters Associated with Recurrence 
The clinical differences between patients with and without recurrences are summarized in 
Table 4. Patients with AF recurrences were more likely to have longer duration of AF prior to 
RFA (9.0 ± 9.4 months vs. 19.3 ± 30.6 months, P = 0.02). Although not statistically 
signiﬁcant, patients who were free from recurrences were more likely to have lone AF 
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(17% vs. 7.2%, P = 0.13). According to the logistic regression analysis, the duration of AF 
prior to RFA (P = 0.04, odds ratio [OR]: 1.03, 95% conﬁdence interval [CI] 1.0–1.1) was 
statistically signiﬁcant predictor for AF recurrence (Table 5.). The percentages of patients 
taking antiarrhythmic drugs were not different with respect to the outcome. 
 
  Patients Without Patients with   
  Recurrence (N = 83)  Recurrence (N = 42)  P 
Clinical Parameters 
  
  
 BSA (m2)  2.1 ± 0.3  2.2 ± 0.3 0.25 
 Age  60.7 ± 8.5 62.5 ± 9.7  0.16 
 CHADS2 score  0.9 ± 0.8 1.1 ± 0.9 0.15 
 Gender (male, %)  69 (83%)  32 (76%)  0.35 
 Hypertension  52 (63%) 31 (74%)  0.21 
 Diabetes mellitus  13 (16%) 6 (14%) 0.8 
 Coronary artery disease  9 (11%) 7 (17%)  0.4 
 COPD 2 (2%)  2 (5%) 0.48 
 Asthma  2 (2.5%) 0 (0%) 0.31 
 Obstructive sleep apnea  18 (22%) 13 (31%)  0.3 
 Lone AF   14 (17%) 5 (7.2%) 0.13 
 Longstanding persistent AF  16 (19%)  13 (31%) 0.1 
 Duration of AF prior to RFA (months)  9.0 ± 9.4  19.3 ± 30.6 0.007 
Medications 
  
  
 β-blocker  57 (71%) 27 (68%) 0.67 
 AAD Class I  25 (31%)  10 (25%) 0.47 
 AAD Class III  24 (30%)  17 (43%)  0.17 
 AAD Class IV  17 (21%)  11 (28%)  0.45 
 Digoxin  6 (8%) 3 (8%) 1 
 
Table 4. Clinical Characteristics of the Patients with and Without Recurrence, CHADS2 
(congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke or TIA or 
thromboembolism). The medications were taken by the patients at the end of the follow-up 
period. RFA = radiofrequency ablation. Abbreviations as in Table I. CI = confidence interval; 
OR = odds ratio. 
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  Univariate 
  Logistic Regression 
  P  OR [95% CI] 
Clinical Parameters 
 
  
 BSA (m2) 0.50  1.8 [0.4–9.13] 
 Age  0.30  1.0 [0.94–1.06] 
 CHADS2 score  0.30  1.3 [0.81–1.9] 
 Gender (male, %)  0.40  0.7 [0.26–1.62] 
 Hypertension  0.20  1.7 [0.7–3.8] 
 Diabetes mellitus  0.84  0.9 [0.31–2.6] 
 Coronary artery disease 0.36  1.6 [0.6–4.8] 
 COPD 0.50  2.0 [0.28–14.9] 
 Obstructive sleep apnea 0.26  1.6 [0.7–3.7] 
 Lone AF  0.14 0.4 [0.1–1.4] 
 Longstanding persistent AF 0.14  1.9 [0.8–4.4] 
 Duration of AF prior RFA 0.04  1.03 [1.0–1.06] 
Medication 
 
  
 AAD Class I  0.50 0.7 [0.3–1.72] 
 AAD Class III  0.17  1.7 [0.8–3.8] 
 AAD Class IV  0.45 1.4 [0.6–3.4] 
 β-blocker  0.70 0.8 [0.4–1.9] 
 Digoxin  1.00  1.0 [0.24–4.2] 
 
Table 5. Logistic Regression Analysis on Clinical Parameters for Predicting Recurrence, 
Abbreviations as in Tables 3 and 4. 
 
Echocardiographic and Atrial Pressure Parameters 
Several echocardiographic parameters were found to be signiﬁcantly different in patients with 
and without AF recurrence, as shown in Table 6. All the LA size measurement at the 4C view, 
including both maximum and minimum lengths, area, and volume measurements, were 
signiﬁcantly correlated with outcome. None of the TDI parameters or direct measured LAP 
was signiﬁcantly different. Among the 2D parameters, LAVimin of 26 cm3/m2 
(P = 0.033, OR 2.5, 95% CI 1.08–5.9) and LAVimax of 42 cm3/m2 (P = 0.015, OR 2.7, 95% 
CI 1.2–5.95) were the best single parameters of AF recurrence after PVI. LAVimax value of 
greater than 40 cm3/m2 is considered severely enlarged according to the American Society of 
Echocardiography guidelines.32 When entered into multiple logistic regression analysis, 
LAVimin of 26 cm3/m2 (P = 0.009, OR: 4.9, 95% CI 1.5–16.2) and duration of AF prior to 
RFA (P = 0.05, OR: 1.03, 95% CI 0.99–1.07) were the independent parameters for AF 
recurrence. 
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  Patients Without  Patients with  P 
  Recurrence (N = 83)  Recurrence (N = 42)  Value 
Echocardiographic Characteristics 2D 
  
  
LA diameter (mm)  43.0 ± 13.5 41.5 ± 14.7  0.3 
LA maximum area (4C, cm2) 23.4 ± 4.9 26.4 ± 5.4 0.002 
LA minimum area (4C, cm2)  17.2 ± 4.4 19.6 ± 4.8  0.004 
LA max. length (4C, cm)  5.2 ± 0.6 5.6 ± 0.7 0.001 
LA min. length (4C, cm)  4.5 ± 0.6  4.8 ± 0.6  0.003 
LA maximum area (2C, cm2)  23.8 ± 4.4  24.9 ± 5.5 0.12 
LA minimum area (2C, cm2)  17.9 ± 4.4  19.0 ± 4.9 0.11 
LA max. length (2C, cm)  5.3 ± 0.7 5.4 ± 0.7  0.21 
LA min. length (2C, cm)  4.5 ± 0.6  4.6 ± 0.7 0.13 
LAVmax (cm3)  92.7 ± 26.0  107.3 ± 31.2  0.005 
LAVmin (cm3)  60.7 ± 20.5  71.9 ± 26.4  0.007 
LAVimax (cm3/m2)  42.5 ± 12.2  49.04 ± 14.9 0.01 
LAVimin (cm3/m2)  27.8 ± 9.6  33.6 ± 12.1  0.005 
LA ejection fraction (%)  34.8 ± 11.0  33.6 ± 13.1 0.3 
PWD 
  
  
E (cm/s)  93 ± 20 94 ± 25  0.41 
Deceleration time (seconds)  198 ± 42 206 ± 39  0.2 
PVS (cm/s)  46 ± 15 45 ± 17  0.4 
PVD (cm/s)  69 ± 20 62 ± 16 0.06 
PVSD  0.7 ± 0.2  0.8 ± 0.3  0.13 
TDI 
  
  
E' lateral (cm) 11.3 ± 3.2 10.8 ± 2.4  0.3 
E' septal (cm)  9.5 ± 2.9  8.8 ± 2.2  0.08 
E' average (cm)  10.3 ± 2.7  9.8 ± 2.1 0.2 
E/E' lateral  9.2 ± 3.9  9.1 ± 3.2 0.5 
E/E' septal  10.7 ± 3.9 11.6 ± 4.9  0.15 
E/E' average  9.9 ± 3.8  10.1 ± 3.7 0.4 
Atrial Pressure (mm Hg) 
  
  
Mean RA pressure  10.5 ± 4.1  10.7 ± 4.2 0.5 
Mean LA pressure  15.1 ± 5.5  16.1 ± 5.9  0.2 
 
Table 6. Invasive and Noninvasive Diastolic Function Parameters, 2C = 2-chamber view; 
4C = 4-chamber view; E = early diastolic peak transmitral flow velocity; E’ lateral, septal, 
avg = annular velocity at lateral, septal side, and the average of them, respectively; LA = left 
atrium; LAA = LA area; LAV = LA volume; LAVi = LA volume indexed to body surface 
area;  LAVmax = LA maximum volume; LAVmin = LA minimum volume;  
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PVD = pulmonary vein diastolic flow velocity; PVS = pulmonary vein systolic flow velocity; 
PVSD = ratio of PVS and PVD; RA = right atrium. 
 
Reproducibility 
Inter- and intraobserver variabilities for echocardiographic measurements are shown in Table 
7. With the exception of the LA diameter measurements in the parasternal long axis view, 
intraobserver variability was minimal. Interobserver agreement was also excellent. 
    Intraobserver    Interobserver 
Parameters  R Difference (%)  R  Difference (%) 
2D 
   
  
LA diameter  0.7   4.5   0.6   1.3 
LA maximum area (4C)  1.0   5.2  0.9   6.7 
LA maximum area (2C)  0.9   2.5   0.8   0.4 
LAVmax 0.9  0.8   0.8   2.4 
LAVmin  0.8   1.5   0.8   7.7 
LAVimax  0.9   2.7   0.8  7.0 
LAVimin  0.8   1.2   0.8   8.3 
PWD 
   
  
E  0.9   2.5  1.0  1.4 
Deceleration time  0.9  0.1  0.9   2.5 
PVS  0.9   2.7   1.0  3.3 
PVD  1.0   1.0   1.0   3.7 
PVSD  0.9  1.1  0.7   1.2 
TDI 
   
  
E' lateral  1.0   2.6   1.0   3.6 
E' septal  1.0   2.0   0.9   3.3 
E/E' lateral  1.0  1.5  0.9  3.6 
E/E' septal  1.0   0.5  0.9   2.7 
E/E' average  1.0  1.0   0.9  2.9 
 
Table 7. Intra- and Interobserver Variability, Abbreviations as in Table 6. 
 
Results 2.  
 
Patient characteristics 
Of 1188 patients who underwent first time catheter ablation between 2004 and 2008, we 
identified 439 consecutive patients with AF recurrence after the blanking period with at least 
18-month follow-up after recurrence. The first recurrence after catheter ablation occurred 
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early (E group: 3–6 months after ablation) in 245 patients, late (L group: 6–12 months after 
ablation) in 118 patients, and very late (VL group: > 12 months after ablation) in 76 patients. 
Patient characteristics among the 3 groups categorized according to the time of recurrence 
after AF ablation were similar in terms of age, type of AF, prevalence of risk factors, and the 
presence of structural heart disease (Table 8). The mean follow-up after initial ablation 
was 50 ± 18 months (maximum 101 months), and the mean follow-up time after recurrence 
was 41 ± 19 months (maximum 97 months). 
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Table 8. Baseline patient characteristics based on the time of AF recurrence after ablation, Continuous variables are expressed as mean ± SD and 
categorical variables as number (percentages). AAD = antiarrhythmic drug; AF= atrial fibrillation; CM= cardiomyopathy. 
  Early group (n= 245) Late group (n= 118)  
Very late group 
(n=76) P  
Time to recurrence after ablation (mo) 3.4 ± 0.7   9.3 ± 2.2  25.8 ± 11.1 <0.001 
Age (y) 57 ± 10   57 ± 9  58 ± 10 0.4 
Sex: Man  185 (76) 91 (77) 57 (75) 0.9 
Body mass index (kg/m2)  29.7 ± 5.5  28.9 ± 4.9  29.7 ± 5.1 0.5 
Hypertension  130 (53) 60 (51) 42 (60) 0.8 
Diabetes mellitus  17 (7) 11 (9) 8 (11) 0.5 
Obstructive slee papnea  44 (18) 18 (15) 15 (21) 0.7 
Coronary artery disease  33 (13) 12 (10) 11 (15) 0.6 
Structural heart disease 34 (14) 9 (8) 7 (9) 0.2 
Left atrial size (mm)  45 ± 7  44 ±7  45 ± 7  0.7 
Left ventricular ejection fraction (%) 57 ± 9  58 ± 10  59 ± 9 0.7 
Paroxysmal AF 144 (59) 67 (57) 42 (60) 0.8 
AF duration (y) 6.9 ± 6.5  6.5 ± 5.5  5.4 ± 4.2 0.1 
Rare AF episodes prior to ablation  44 (18) 13 (11) 10 (13) 0.4 
Number of failed AADs 1.6 ± 0.9  1.5 ± 0.9  1.3 ± 0.8 0.1 
Patients never on any AAD prior to ablation 25 (10) 13 (11) 10 (13) 0.3 
Tachycardia-mediated CM 24 (10) 12 (10) 9 (13) 0.9 
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Recurrences during the 3-month blanking period 
During the blanking period, 306 of 439 (70%) of the study patients had arrhythmia episodes. 
Patients with early recurrences (3–6 months after ablation) were more likely to have had AF 
during the blanking period compared with patients with late and very late recurrences (201 of 
245 (82%) in the E group vs. 64 of 118 (54%) in the L group and 41 of 76 (54%) in the VL 
group; P < 0.001 for comparison across groups). DCCV was performed during the blanking 
period in 79 of 201 (39%) in the E group, 28 of 64 (40%) in the L group, and 22 of 41 (54%) 
in the VL group (P = 0.2). In total, 19 patients underwent a repeat ablation procedure during 
the blanking period, with no statistically significant difference between groups (13 of 201 
(6%) in the E group, 3 of 64 (5%) in the L group, and 3 of 41 (7%) in the VL group; (P = 0.8). 
 
AF recurrences after the blanking period 
At the time of recurrence after the blanking period, 144 of 245 (59%) patients in the E group 
were on an AAD in comparison to 37 of 118 (31%) patients in the L group and 5 of 76 (7%) 
patients in the VL group (P < 0.001). To treat recurrences, a total of 159 patients underwent at 
least 1 DCCV, without statistically significant differences among the 3 groups (81 of 245 
[33%] in the E group, 45 of 118 [38%] in the L group, and 33 of 76 [43%] in the VL 
group; P = 0.2). Forty-two of 439 patients (9.5%) recurred with atrial flutter or atrial 
tachycardia, with no statistical differences among the groups (30 of 245 [12%] in the E group, 
7 of 118 [6%] in the L group, and 5 of 76 [7%] in the VL group; P = 0.1). The presence of 
only subsequent rare AF recurrences was significantly higher in L and VL groups than in the 
E group (Figure 4.). Only 23 of 245 [9%] patients in the E group had no or rare 
AF (≤ 2 episodes or ≤ 1 DCCV during any 6-month window from the first recurrence) in 
comparison to 50 of 118 (47%) patients in the L group and 52 of 76 (68%) in the VL group 
(P < 0.001 for comparison across groups and for comparison between L and VL groups). 
There was no significant difference in the subsequent frequency of rare AF between those 
whose initial recurrence required DCCV and those whose initial recurrence did not require 
DCCV (39 of 141 [27.7%] vs. 86 of 298 [28.9%], respectively; P = 0.8).  
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Figure 4. Influence of early (E), late (L), and very late (VL) recurrences after catheter 
ablation on the presence of no or only rare atrial fibrillation (AF) during follow-up and 
response to antiarrhythmic drugs (AADs) among all patients, *P < 0 .05; **P < 0 .001. 
 
Univariate factors predictive of rare arrhythmia episodes after recurrence are depicted 
in Table 9. Type of AF and patient clinical characteristics did not predict subsequent rare 
arrhythmia episodes after the initial AF recurrence. In multivariate analysis, the strongest 
independent predictors of rare AF after the initial AF recurrence were late and very late time 
of recurrence after the procedure. 
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  Univariate Multivariate 
  OR  95% CI   P OR 95% CI  P 
AF in the blanking period  0.3 0.2–0.4  <0.001 0.5 0.3–0.9 0.03 
DCCV in the blanking period  0.6 0.4–1.1 0.06 0.93 0.5–2 0.9 
On AAD at the time of recurrence  0.2 0.1–0.3 <0.001 0.5 0.3-0.9 0.03 
L recurrence group*   7.09   4.03–12.5  <0.001  5.07 2.8–9.2 < 0.001 
VL recurrence group*   20.8   10.9–40 <0.001  13.8 6.9–27.7 < 0.001 
 
Table 9. Factors predictive of rare AF after the initial recurrence, AAD= antiarrhythmic drug; AF= atrialfibrillation; CI= confidence interval; 
DCCV= direct current cardioversion; L= late (6–12 mo after ablation); VL= very late (> 12 mo after ablation). *Relative to the E recurrence 
group, OR= Odds Ratio 
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Efficacy of antiarrhythmic drug therapy after recurrence 
AADs were tried in 108 of 245 (44%), 65 of 118 (55%), and 32 of 76 (42%) patients in the E, 
L, and VL recurrence groups, respectively (P = 0.1 for comparison across groups). Seventy-
two patients were started on a new AAD despite having rare arrhythmia episodes before AAD 
initiation (17 of 108 [16%] in the E group, 38 of 65 [58%] in the L group, and 17 of 32 [53%] 
in the VL group; P < 0.001). There were no differences in the type of drug used among the 
groups; class III AADs were the most frequently selected (49%), followed by class I AADs 
(33%) and amiodarone (13%). Patients in the VL group were more likely to respond to AADs 
with the elimination of AF during subsequent follow-up than patients with early and late 
recurrences (23 of 32 [72%] showed positive response in the VL group vs. 21 of 108 [19%] in 
the E group and 38 of 65 [58%] in the L group; P < 0.001) (Figure 1A). The difference was 
maintained regardless of the frequency of episodes prior to initiating AADs (8 of 15 [53%] 
showed positive response in the VL group vs. 13 of 91 [14%] in the E group and 9 of 27 
[33%] in the L group; P = 0.001). Patients with paroxysmal AF, those who did not recur 
during the blanking period, those not on AADs at the time of recurrence, and those with rare 
AF episodes after recurrence had a better response to AADs. The class of AADs did not 
impact positive response (44% class III, 38% class I, 32% amiodarone; P = 0.6), nor did other 
clinical baseline characteristics. In a multivariate model, baseline paroxysmal AF, the time to 
AF recurrence after ablation, and rare AF prior to initiating or changing AADs were 
independent predictors of a positive response to AAD therapy after the initial recurrence 
(Table 10). 
  Univariate Multivariate 
  OR 95% CI  P OR 95% CI  P 
Paroxysmal AF  1.7 0.9–3.05 0.06   2.2 1.05–4.6 0.04 
AF in the blanking period   0.3 0.2–0.5 < 0.001  0.6 0.2–1.4 0.2 
CV of AF in the blanking period  0.5 0.3–0.9 0.04  0.7 0.3–1.6 0.4 
On AAD at the time of 
recurrence   0.3 0.1–0.6 0.001  0.8  0.3–2 0.7 
Rare AF before ADD   8.9 4.6–17.2  <0.001  5.4 2.5–11.7 < 0.001 
L recurrence group*  5.8  2.9–11.6  <0.001   3.1 1.4–6.8 0.004 
VL recurrence group*   10.5  4.3–26.2  <0.001   6.7 2.4–18.9  < 0.001 
 
Table 10. Factors predictive of no AF on AADs after recurrence, AAD = antiarrhythmic 
drug; AF = atrial fibrillation; CI = confidence interval; DCCV = direct current cardioversion; 
L = late (6–12 mo after ablation); VL = very late (> 12 mo after ablation). *Relative to the E 
recurrence group, OR= Odds ratio 
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Repeat ablation and outcome 
In this study cohort, 290 patients underwent repeat ablation (185 of 245 [75%] in the E group, 
70 of 118 [59%] in the L group, and 35 of 76 [46%] in the VL group; P < 0.001) (Figure 5.). 
Patients in the E group were the most likely to pursue repeat ablation owing to frequent 
symptomatic recurrences (79% in the E group vs. 47% in the L group and 29% in the VL 
group; P < 0.001). In patients with recurrences after 6 months, the decision to pursue repeat 
ablation was more often driven by patient preference for ablation over continued AADs (31% 
in the VL group and 28% in the L group vs. 10% in the E group; P = 0.001), by the need for 
cardioversion or by the persistent nature of the AF recurrence (31% in the VL group and 24% 
in the L group vs. 13% in the E group; P = 0.01). Two patients in each group underwent a 
repeat procedure because of tachycardia-induced cardiomyopathy, tachycardia-bradycardia 
syndrome, or episodes of heart failure associated with AF. After the second procedure, 241 
patients had at least 1-year follow-up. Patients in the VL group had the highest rate of AF 
control (no or rare episodes for each year of follow-up) after repeat ablation (24 of 27 [89%] 
vs. 38 of 54 [72%] in the L group and 78 of 160 [49%] in the E group; P < 0.001) (Figure 5). 
Other factors predictive of AF control after repeat AF ablation in univariate analysis included 
paroxysmal AF, LA size, the duration of AF, recurrences in the blanking period, and the 
presence of rare AF after recurrence. In multivariate analysis, the type of AF, LA size, the 
duration of AF history prior to ablation, and the time of recurrence after ablation 
independently predicted AF control after repeat ablation (Table 11). 
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Figure 5. Influence of early (E), late (L), and very late (VL) recurrences after catheter 
ablation on the rate of repeat ablation and > 1-year atrial fibrillation (AF) control after repeat 
ablation in all patients. *P < 0.05; **P < 0.001 
  Univariate Multivariate 
  OR 95% CI  P  OR 95% CI  P 
LA size (mm)  0.9 0.92–0.99 0.03 0.9 0.9–0.99 0.03 
Paroxysmal AF  2.08 1.2–3.5 0.006  2.5 1.2–4.9 0.009 
AF duration before ablation (y)  0.9 0.9–0.98 0.003 0.9 0.9–0.98 0.009 
AF in the blanking period  0.5 0.3–0.9 0.02 0.7 0.3–1.7 0.3 
Rare AF after recurrence  2.8 1.3–5.9 0.008  1.5 0.5–4.5 0.4 
L recurrence group*   2.5  1.3–4.8 0.007  1.7 0.7–3.9 0.2 
VL recurrence group*   8.4  2.4–29.05 0.001  7.4 1.5–36.9 0.014 
 
Table 11. Factors predictive of AF control after repeat ablation procedure, 
AAD = antiarrhythmic drugs; AF = atrial fibrillation; CI = confidence interval; LA = left 
atrium; L = late (6–12 mo after ablation); VL = very late (> 12 mo after ablation). *Relative 
to the E recurrence group. OR = Odds ratio 
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Outcome of patients without repeat AF ablation 
The 149 patients who did not undergo a repeat ablation had a clinical course that varied based 
on the time of their first AF recurrence after the original ablation (Figure 6). Patients with 
very late recurrences did extremely well. Of the 41 patients in the VL group who did not 
undergo repeat ablation, 15 were free of AF after the initial recurrence and 24 experienced 
only rare subsequent AF recurrences (39 of 41 [95%] patients with good outcomes, with a 
mean maximum arrhythmia-free interval of 21 ± 7 months). Of the 48 patients in the L 
recurrence group, 10 were free of AF and 27 patients had rare AF recurrences (37 of 48 [77%] 
patients with good clinical outcome with a mean maximum arrhythmia-free interval of 
16 ± 5 months). In contrast, of the 60 patients in the E group who did not undergo repeat 
ablation, only 3 patients remained arrhythmia-free and 19 had rare AF episodes after the first 
recurrence (22 of 60 [37%] patients with good outcomes, with a mean maximum arrhythmia-
free interval of 14.9 ± 3.9 months; P < 0.001 vs. L and VL groups). In patients who continued 
to have frequent episodes, 10 patients were treated with rate control, 1 underwent 
atrioventricular junction ablation, and 9 patients had been scheduled for a repeat ablation 
procedure after the end of the follow-up. Thirty patients had more than 2 episodes per 
6 month follow-up window or > 1 cardioversion but declined a repeat AF ablation procedure. 
Patients not undergoing repeat ablation with favorable outcome were less likely to have AF 
recurrence in the blanking period, less frequently on AAD at the time of AF recurrence after 
the blanking period, and had rare episodes in the first 6 months after recurrence. In 
multivariate analysis, the time of recurrence after ablation was the only independent predictor 
of no or rare arrhythmia episodes and patients in L and VL groups had more favorable 
outcome than did patients in the E recurrence group (Table 12). 
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Figure 6. Influence of early (E), late (L), and very late (VL) recurrences after catheter 
ablation on the development of more frequent atrial fibrillation (AF), defined as > 2 AF 
episodes or > 1 cardioversion in any 6-month follow-up window. Included are all patients 
without repeat ablation and at least 30-month follow-up. 
  Univariate Multivariate 
  OR 95% CI   P OR 95% CI   P 
AF in the blanking period  0.2 0.08–0.5 <0.001  0.4 0.1–1.1 0.06 
Rare AF in the first 6 mo after first 
recurrence  4.5 2.2–9.4  <0.001   1.2 0.4–3.2 0.7 
On AAD at the time of recurrence  0.3 0.1–0.6 0.002  0.8 0.3–2.4 0.9 
L recurrence group*   5.8  2.4–13.7  <0.001   3.9 1.5–10.2 0.004 
VL recurrence group*   33.3   7.4–142.8 <0.001   23.8 4.6–125  <0.001 
 
Table 12. Factors predictive of no or rare AF without repeat ablation after recurrence, 
AAD = antiarrhythmic drugs; AF = atrial fibrillation; CI = confidence interval; L = late (6–12 
mo after ablation); VL = very late (> 12 mo after ablation). *Relative to the E recurrence 
group, OR = Odds ratio 
 
Outcomes in paroxysmal and nonparoxysmal AF 
Patients with both paroxysmal and persistent AF demonstrated the same influence of the time 
of AF recurrence after ablation on clinical outcome (Figure 7, Figure 8, Figure 9). 
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Figure 7. Influence of early (E), late (L), and very late (VL) recurrences after catheter 
ablation on the presence of no or only rare atrial fibrillation (AF) during follow-up and 
response to antiarrhythmic drugs (AADs) among all patients (A). Mean follow-up was 41 
months. A similar response was observed among patients with paroxysmal (B) and persistent 
AF (C). *P < 0.05; **P < 0.001. 
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Figure 8. Influence of early (E), late (L), and very late (VL) recurrences after catheter 
ablation on the rate of repeat ablation and 1 > year atrial fibrillation (AF) control after repeat 
ablation. A: All patients. B: Patients with paroxysmal AF. C: Patients with nonparoxysmal 
AF. *P < 0.05; **P < 0.001. 
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Figure 9. Influence of early (E), late (L), and very late (VL) recurrences after catheter 
ablation on the development of more frequent atrial fibrillation (AF), defined as > 2 AF 
episodes or > 1 cardioversion in any 6-month follow-up window. Included are all patients 
without repeat ablation and at least 30-month follow-up (A). In contrast to patients with early 
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recurrences, patients with late recurrences typically had good outcome with no or infrequent 
AF during long-term follow-up. Results were similar for patients with paroxysmal (B) and 
persistent AF (C). 
Results 3.  
 
Mechanism of postoperative atrial tachycardias 
One hundred patients had 151 atrial tachycardias (ATs) during 127 procedures—88 (58%) 
CTI-dependent flutters, 34 (22.5%) RA incisional tachycardias, 12 (8%) perimitral flutters, 4 
(3%) LA roof dependent flutters, 1 (0.7%) upper loop reentry, an unmapped LA flutter (failed 
transseptal access), and 11 (7%) focal ATs. Eighty-eight patients had CTI-dependent flutter, 
and 49 patients had at least one non-CTI-dependent flutter. Eleven patients had focal atrial 
tachycardia. Focal ATs originated from the vicinity of surgical scar in 4 (36%) of 11 cases 
(three from the RA free wall atriotomy, one from a septal ASD patch). Other origins of focal 
AT were at the LA roof, the pulmonary veins and the mitral ring in two (18%) patients each 
and the tricuspid ring in one (9%). In the case of 15 patients, atrial fibrillation was also 
observed during the procedure. The CARTO™ XP system was used for mapping in 69 
procedures. Most CTI-dependent AFLs (64%) were ongoing at the commencement of the 
procedure, while 18% occurred by transformation during ablation of another AT and 18% 
were induced by extrastimulation during sinus rhythm. The proportions of 
ongoing/ transformed/ induced ATs were 41%/ 35%/ 24% of RA incisional, 67%/ 17%/ 17% 
of perimitral, 50%/ 25%/ 25% of roof dependent flutters, and 18%/ 46%/ 36% of focal 
tachycardias. 
 
Distribution of atrial tachycardias between surgical groups 
Of the 20 patients with RA appendage cannulation, 19 (95%) had CTI-dependent flutter, three 
(15%) had a non-CTI-dependent AFL, and none had focal AT. All non-CTI-dependent AFLs 
in this group were RA incisional tachycardias related to the cannulation site of the RA. In 
patients with RA free wall atriotomy, a CTI-dependent AFL was seen in 30 of 32 (94%) 
patients, a non-CTI-dependent AFL in 13 (41%) and focal AT in four (13%). Eleven of the 13 
(85%) non-CTI-dependent AFLs were RA incisional tachycardias related to the right 
atriotomy; there was one (8%) perimitral AFL and one upper loop reentry in this group. 
Among patients with transseptal LA atriotomy the frequency of CTI-dependent flutter was 
83% (34 of 41 patients), while at least one non-CTI-dependent AFL was seen in 30 patients 
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(73%). One patient (2%) had two non-CTI-dependent circuits. Focal AT occurred in six 
(15%) patients. The most frequently encountered non-CTIdependent AFL was again RA 
incisional tachycardia—20 of 31 circuits (65%), while seven (23%) perimitral and three 
(10%) LA roof-dependent AFLs were mapped in this group. One LA AFL was not mapped 
due to failed transseptal access. Five of seven (71%) patients had CTI-dependent AFL in the 
direct LA atriotomy group and four patients (57%) had non-CTI-dependent AFLs. One patient 
(14%) had two non-CTI-dependent circuits and one had focal AT. Perimitral was the most 
common non-CTI-dependent AFL—4 of 5 (80%) circuits, while one (20%) LA roof-
dependent AFL was diagnosed in this group. 
 
Comparison of AT mechanisms between surgical groups 
The frequency of CTI-dependent AFL was not different between groups (P = 0.195). A non-
CTI-dependent AFL, on the other hand, was seen progressively more frequently with more 
extensive atrial incisions (P < 0.001)—15% of patients who had simple venous cannula 
insertion, 41% and 57% after RA and LA atriotomy, respectively, and 73% of patients after 
biatrial access (transseptal left atriotomy). After operations involving the RA, the most 
common nonCTI-dependent circuit was that of a RA incisional tachycardia, seen more 
commonly in patients who had RA atriotomy as opposed to those who had only RA 
appendage cannulation (43% vs. 15%, P = 0.024). Perimitral AFL was seen more frequently 
in cases where the LA was opened compared with operations involving only the RA—22% 
versus 2%, respectively (P =0.002), and the same was true for LA roof-dependent AFL (8% 
vs. 0% P = 0.041). There was no significant difference in the frequency of focal AT between 
groups (Table 13.) 
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Atrial tachycardia  Atrial incision         
  
RA 
cannulation  
RA atriotomy  Transseptal LA atriotomy  Direct LA atriotomy P value 
  (n=20) (n=32) (n=41) (n=7)   
CTI-dependent AFL  95% 94% 83% 71% 0.191 
Non-CTI-dependent AFL  15% 41% 73% 57%  <0.001 
 RA incisional  15% 34% 49% 0%  0.013 
 Perimitral  0% 3% 17% 57%  <0.001 
 LA roof-dependent  0% 0% 7% 14%  0.147 
Focal AT  0% 13% 15% 14%  0.365 
 
Table 13. Comparison of AT mechanisms between surgical groups, RA right atrium, LA left atrium, CTI cavotricuspid isthmus, AFL atrial 
flutter, AT atrial tachycardia. 
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Multivariate analysis 
Age, sex, history of hypertension, congenital heart disease, ischemic heart disease, valve 
surgery and preprocedural echocardiographic dimensions (LA diameter, end-diastolic, and 
end-systolic left ventricular diameter) were analyzed in respect to the different AT 
mechanisms. When any of these parameters was significantly related to a specific AT, it was 
included in multivariate analysis using logistic regression. No predictor was recognized for 
CTI-dependent AFL, which was equally prevalent in all groups. With non-CTI-dependent 
AFL, surgical group and larger LA diameter showed significant correlation, but only surgical 
group proved to be an independent predictor in multivariate analysis (P <0.001). Only 
surgical group was associated with RA incisional tachycardia (P = 0.011). Perimitral AFL 
besides being related to surgical group showed a positive association with LA diameter 
(P = 0.039) and valve surgery (P = 0.016), negative association with left ventricular end-
diastolic and end-systolic diameters (P = 0.030 and P = 0.043, respectively). With 
multivariate analysis surgical group and end-systolic diameter remained independent 
predictors of perimitral AFL (P = 0.019 and P = 0.036, respectively). Left atrial atriotomy was 
the only predictor for LA roof-dependent AFL (P = 0.041). No predictor was identified for 
focal AT. 
 
Radiofrequency ablation 
In the case of CTI-dependent AFLs, linear ablation of the CTI was performed until 
termination of the tachycardia and establishment of bidirectional conduction block of the CTI. 
This was successful in 87 of 88 (99%) cases, while in one case AFL terminated, but CTI 
block could not be achieved. All 34 RA incisional tachycardias were ablated successfully: 
tachycardia terminated in 28 cases when a linear ablation lesion was placed between the 
atriotomy and the inferior vena cava, in one case between the atriotomy and a septal scar, in 
two cases between the atriotomy and the tricuspid ring, and in three cases when narrow 
channels were closed within the scar of the lateral RA atriotomy. Complete conduction block 
along these lines was confirmed by electroanatomical mapping demonstrating an activation 
detour during pacing close to the line in all cases. In case of perimitral flutter linear ablation at 
the mitral isthmus was attempted first, except for one case where a narrow channel was noted 
between the anteroseptal atriotomy scar and the mitral annulus. A single radiofrequency 
lesion at this site terminated the tachycardia and rendered it noninducible (Fig.3.). Mitral 
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isthmus ablation led to the termination of the arrhythmia and development of conduction 
block in six of the other 11 (54.5%) cases. In two of the remaining five cases epicardial 
ablation in the CS at the level of the endocardial ablation line led to conduction block, while 
in three cases this was also unsuccessful. In one of these cases, the tachycardia terminated, but 
conduction block could not be achieved, and in one other case, an anterior ablation line from 
the mitral annulus to the left upper pulmonary vein terminated the AFL. Perimitral AFL of 
one patient could not be terminated by ablation. Three off our LA roof-dependent AFLs were 
ablated by linear ablation between upper pulmonary veins and one by mitral isthmus ablation. 
All focal ATs were successfully terminated by ablation and rendered noninducible. 
 
Follow up 
Twenty-one patients were lost to follow up; the rest were followed for 19 ± 15 months. 
Seventeen patients (22%) had recurrent AFL, and 21 (27%) had atrial fibrillation during 
follow up. Recurrent AFL was more common in patients who had operations involving the 
LA (8% vs. 30%, P = 0.015). Patients who developed atrial fibrillation during follow up had 
larger LA diameter (57 vs. 52 mm, P = 0.028). No other parameters showed an association 
with recurrent AFL or atrial fibrillation. 
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Discussion  
 
1.  
We investigated clinical and echocardiographic parameters for AF recurrence after RFA in 
patients with persistent and longstanding persistent nonvalvular AF, and found LA size 
measurements in the 4C view, including length, area, and both maximum and minimum 
volumes, to be superior to any other diastolic function parameters and directly measured LA 
pressure in association with recurrence in this patient population. 
Echocardiography is a very important tool to evaluate AF patients. Several studies showed 
that LA enlargement was a well-recognized risk factor for recurrence after cardioversion and 
catheter ablation.33-35 Recent studies showed that noninvasive assessment of LV filling 
pressure can help to predict recurrence after SR is restored.12 
The restoration of SR is much more challenging in patients with persistent and longstanding 
AF, probably due to more advanced remodeling. The previous studies evaluated the predictors 
in a mixed study population including paroxysmal, persistent, and longstanding persistent AF 
patients.36,37,12,13 Our study focused on patients with persistent and longstanding persistent AF 
and we evaluated clinical, invasive, and noninvasive diastolic function parameters. Our 
finding highlighted the significance of LA enlargement in ablation outcome in these patients. 
 
Clinical Parameters and Recurrence of AF 
We found that the duration of AF prior RFA was the only significant clinical parameter 
correlated with AF recurrence. A recent study also showed that the duration of AF is an 
important predictor of SR maintenance after RFA, although the literature is controversial 
regarding this finding.11,36,38 Longstanding AF may lead to atrial fibrosis and the development 
of AF substrate through structural remodeling. AF associated structural and 
pathophysiological changes are very important factors that promote remodeling10 and might 
have a role in catheter ablation outcome. 
 
Echocardiographic Parameters and Recurrence of AF 
Our study is the first to evaluate both the invasive and noninvasive diastolic function 
parameters in association with AF recurrence after RFA in one setting in patients with 
persistent AF. Recent studies showed that diastolic function parameters might be able to 
predict AF recurrences after PVI; however, these parameters were assessed individually. LAV 
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assessed by computer tomography was shown to be a potential predictor of AF recurrence.14,36 
The ratio of E/E’has been shown to be a useful parameter to predict SR maintenance.12 LA 
remodeling plays an important role in initiation and perpetuation of AF. The reversibility of 
this remodeling depends on the strength and the duration of exposure to stressors. The most 
common stressors of atrial myocytes are volume/pressure overload and tachycardia. Increased 
volume/pressure overload leads to chamber dilatation and stretch of the myocardium, 
providing a substrate for AF.10 Supporting this concept, LA size has been shown to 
correspond with atrial fibrosis39 and the development of fibrosis leads to LA dilation and 
subsequently AF.40 Although the mean LAP was not significantly different in patients with 
and without arrhythmia recurrence, the structural changes shown by LAV parameters may 
reflect duration of exposure. We suspect that the 4C view measurements are superior for LA 
size because the entire LA is well visualized in this view due to optimized ultrasound probe 
position for this view as compared to the 2C or the parasternal long axis view. A recent study 
showed minimal LAV might be superior to maximum LAV for prediction of first AF and/or 
atrial flutter in an elderly cohort.41 Our results substantiate this study in a younger population 
with persistent AF. LA minimum volume might be less dependent on loading conditions than 
LA maximum volume, and is therefore a better presentation of LA size. 
 
2.  
The major finding of this study is that the time to AF recurrence after catheter ablation 
dramatically influences clinical outcome. The longer the time to AF recurrence, the more 
likely that a patient will have a good clinical course with infrequent additional AF episodes, 
more drug responsiveness and an excellent response to repeat catheter ablation. 
 
Comparison with previous studies 
The benign pattern of very late AF recurrences has been previously suggested.42,43 However, 
these prior studies were limited by small size and included few patients with nonparoxysmal 
AF.42,43 Our study is unique in reporting long-term outcome of a large cohort of patients with 
paroxysmal and nonparoxysmal AF with after ablation AF recurrences after the initial 
procedure. Our study is also unique in its attempt to define outcome based on the time of 
recurrence after ablation by dividing the population into 3 clinically meaningful subgroups: 
early recurrences (3–6 months), late recurrences (6–12 months), and very late recurrences 
(>12 months) after ablation. Furthermore, we sought to identify (1) patients with only rare AF 
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episodes during the long-term follow-up after the first AF recurrence and (2) responsiveness 
to AADs and repeat catheter ablation, as indices of a more “benign” clinical course. Patients 
with recurrences in the first 3–6 months after ablation represented the largest group in our 
study. These patients had the least favorable outcomes in that most had subsequent frequent 
AF and did not respond to new AADs when tried. Most of these patients were already on 
AADs (59%), and a decision to pursue repeat ablation was frequently chosen as the preferred 
therapeutic option. The outcome was worse in comparison to the other groups after the second 
ablation attempt, and significantly more ablation procedures were necessary in this group to 
achieve a level of AF control comparable to those with late rrecurrences. Patients with 
recurrences between 6 and 12 months have been previously designated as both early 
recurrences and late recurrences.44,45 However, we showed that this group of patients is 
clinically different from patients with recurrence between 3 and 6 months after ablation and 
those with recurrence > 12 months after ablation. This group represents an “intermediate” 
group, with outcomes after recurrence falling between those of patients who had E and VL 
AF recurrences. In this large consecutive group of patients, we demonstrate that patients with 
VL recurrence are less common than those who recur earlier after ablation. Our incidence of 
6.4% for late AF is comparable to the 5.0%–7.8% reported in smaller series.46 Importantly, 
additional AF recurrences after 1 year tend to occur as rare episodes and have a better 
response to AADs. Even patients with recurrence after a year who had frequent AF episodes 
responded better to AADs than their counterpart patients whose AF recurred earlier after 
ablation. In addition, patients with very late recurrences underwent less repeat ablations, and 
when performed, the results of repeat ablation were associated with better clinical outcome. 
Most patients ultimately could be maintained off AADs. It is important to note that a 
significant number of patients with recurrence after AF ablation had a good clinical outcome 
after a single procedure, although they were not completely arrhythmia-free. In patients with 
AF recurrences after 6 and 12 months who did not undergo repeat ablation, our data show 
77% and 95% of these patients, respectively, experience no or very sporadic AF episodes 
after their initial recurrence, with long arrhythmia-free intervals (Figure 9).  
 
Other factors associated with the time of recurrence after AFablation and clinical outcome 
There was a higher incidence of recurrences in the blanking period in patients with E 
recurrences in comparison to those with L or VL recurrences (82% vs. 54%; P = 0.001). This 
suggests that patients included in the E group represent a subset of patients who may have 
already developed acute PV reconnection. Of interest, patients with E recurrences also had a 
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longer history of AF in comparison to those with VL recurrences, which may imply that these 
patients have a more arrhythmogenic substrate. It is well described that AF promotes atrial 
remodeling, which leads to a more resistant substrate for treatment.10 Longer duration of AF 
has been shown to be an independent predictor of recurrences after ablation in previous 
studies,45 and we have shown that it is also an independent predictor of frequent arrhythmia 
episodes after the initial recurrence and repeat ablation. In addition, recurrence during the 
blanking period predicted more frequent subsequent AF episodes and a more troublesome 
clinical course. Nonparoxysmal AF is associated with worse outcome after catheter ablation. 
However, it is of interest that both patients with paroxysmal and nonparoxysmal AF in the E 
recurrence group had a poorer response to AADs, were unlikely to have only rare AF during 
subsequent follow-up (Figure 1), and had a worse outcome after repeat ablation. These 
findings highlight the primary influence of the time of recurrence on clinical outcome 
regardless of AF type.  
 
Mechanistic implications for the influence of the time of recurrence after ablation on 
subsequent clinical outcome  
While 97% of the patients undergoing repeat AF ablation have reconnected PVs, it could be 
that patients with late recurrence have less extensive areas of reconnection, which result in 
more limited PV to LA conduction and, consequently, fewer recurrences and better response 
to AADs. Verma et al47 reported that patients who maintained sinus rhythm on AADs had a 
significant conduction delay between reconnected PVs and the LA whereas patients who did 
not respond to AADs had only a minimal conduction delay. In the present study, we did not 
find differences related to primary ablation strategy and time of recurrence, possibly because 
of the uniformity of the ablation procedure during the study period. 
 
3.  
This study has shown that the finding of non-CTI-dependent AFL at electrophysiology study 
performed for clinical AT occurring late after open heart surgery is strongly associated with 
the atrial incisions applied during the operation. While CTI-dependent AFL is the most 
common AT in all groups, a non-CTI-dependent, atypical AFL becomes progressively more 
common with more extensive atrial incisions. Of the different non-CTI-dependent circuits, 
RA incisional tachycardias dominant after surgery involving the RA, while a perimitral or LA 
roof-dependent circuit can be expected after LA operations. Focal AT was not correlated with 
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atriotomy, but—other than the typical predilection sites—showed a tendency to originate 
from the vicinity of surgical scar.  
 
Comparison with previous studies 
Lukac et al. 48 could not show a difference in the distribution of different atrial tachycardias 
developing after cardiac surgery for a wide range of indications. They included patients with 
complex congenital heart disease, heart transplantation, and maze procedure and adopted a 
classification for AT based only on the mechanism ("incisional" and "not incisional") rather 
than the location of the circuit. Our patients represent a more routinely encountered 
population with postoperative arrhythmias presenting to a center not specifically involved in 
the management of patients after heart transplantation. Furthermore, our classification of AT 
is different: not only by mechanism (focal or AFL) but by the common location (e.g., RA free 
wall) and ablation strategy of the AT. For the above reasons, our results are not directly 
comparable to those of Lukac et al. Nevertheless, they also show the most frequent AT late 
after cardiac surgery to be CTI-dependent AFL. Also, the reported frequencies of RA 
incisional tachycardia among their patients comparable to our groups (after right lateral 
atriotomy and transseptal approach to the mitral valve) are very similar to our results (33% 
and 40%, respectively).48 In the largest reported series of postoperative AFL, Aktas et al. 
found CTI-dependent AFL to be most common. Similar to our results, the indication for 
surgery (valve- or onvalve-related) did not influence the type of AFL. However, the 
association between atrial incisions and type of AFL was not specifically studied.23 
 
Cavotricuspid isthmus-dependent postoperative flutter 
Functional and/or fixed block to impulse propagation between the venae cavae favors the 
development of this arrhythmia after heart surgery.49,50 Many studies have found the dominant 
role of the CTI in postoperative AFL mechanism23,24,48, while others have shown incisional 
tachycardia, depending on an isthmus bordered by an atrial incision to be most frequent.19, 25, 
51-53 In the study by Anné et al.18, CTI-dependent flutter predominated in the congenital heart 
disease group, while RA incisional tachycardia was more frequent in a group of patients with 
acquired heart disease and mostly mitral valve operations. According to our results, CTI-
dependent AFL is the most common AT after open heart surgery in all groups, and the 
relative frequencies of CTI-dependent and non-CTI dependent AFL circuits are related not to 
the underlying heart disease but more to the atrial incisions created during the operation. 
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Right atrial incisional tachycardia 
While an intercaval line of block favors classical AFL development, a sufficiently long, fixed 
barrier in the RA free wall may predispose to incisional tachycardia.49,54A surgical incision on 
the RA free wall facilitates the development of this arrhythmia, however, the extent and 
position of the lesion seems to be an important factor. In this study, among patients who 
underwent venous cannulation only (at the RA appendage), 15% had RA incisional 
tachycardia, but among patients who had a long RA free wall atriotomy, this AT was seen in 
43% (Fig. 2.). This latter group comprised patients after open cannulation of the coronary 
sinus for retrograde cardioplegia, a procedure reported previously to be arrhythmogenic55 and 
to favor RA incisional tachycardia.25 Also included in this group were patients after atrial or 
ventricular septal defect closure or tricuspid valve operation. These operations are also known 
for their potential to result in late RA incisional AFL.56 This tachycardia was found to be most 
common (49% of patients) when the RA free wall atriotomy was prolonged to the roof of the 
RA, between the superior caval vein and the tricuspid annulus, and further onto the interatrial 
septum during transseptal LA atriotomy. The longer incision may favor peri-lesional AFL by 
a longer path length of reentry, more likely development of slow conduction at sites of 
reconnection along the long lesion or in the longer corridor between the incision and the 
tricuspid annulus.57 Also, the more anteriorly placed incision is more likely to cause peri-
incisional reentry as shown by Tomita et al.49 The rotating wavefront either uses the isthmus 
between the incision and the inferior caval vein, or a channel of reconnection along the lesion, 
but always uses at least some part of the corridor between the incision and the tricuspid 
annulus. Reconnection can occur anywhere along this line thereby connecting the two sides of 
the incision and closing the reentrant circuit, which can be located both septally 58 or more on 
the free wall57 in this group of patients. Isolated channels or a narrow corridor might allow for 
focal ablation.19, 58 Otherwise, the arrhythmia can be terminated by a linear lesion connecting 
the incision to another barrier: the inferior vena cava or tricuspid annulus.60 This suggests that 
extension of the incision towards the inferior caval vein and/or surgical ablation to connect 
with the tricuspid annulus at the time of surgery might prove to be effective against the future 
occurrence of this arrhythmia.  
 
Left atrial flutters 
The LA is a much less common site than the RA for AFL, both in patients with and without 
prior cardiac surgery.23 Nevertheless, the finding of LA flutter is more frequent after 
surgery.23 Similarly to classical peritricuspid flutter after RA incisions, surgical scar in the LA 
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may pave the way for perimitral reentry. This is supported by the fact that this arrhythmia was 
seen almost exclusively after operations involving the LA in this series. However, similar to 
previous experience61,62, roof-dependent LA flutters also occurred in this group of patients, 
using the pulmonary veins and LA scar as the central obstacle.  
 
Focal atrial tachycardia 
Focal AT was an uncommon finding in these patients late after open heart surgery, similarly 
to previously reported series of operated congenital heart disease.63 The arrhythmia originated 
from the vicinity of surgical scar in more than one third of the cases—a previously reported 
finding after operation for congenital heart disease.22 Other sites of origin of focal AT, 
including the AV rings and pulmonary veins, are typical predilection sites in normal hearts 
also.64 
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Conclusion 
Atrial fibrillation and atrial flutter play an essential role in atrial remodeling, and atrial 
tachycardias lead to several adverse clinical consequences such as impairment of quality of 
life, embolic events and congestive heart failure. Catheter ablation is a very important tool in 
the treatment of these atrial tachycardias, hereby it helps to slow down and inhibit the process 
of remodeling. Optimal patient selection, the detailed knowledge of atrial anatomy and the 
type atrial incisions applied during open heart surgery could be the key to the success of the 
procedure.  
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New observations 
1. Results of this study demonstrate the importance of indexed LAV in association with 
recurrence in patients with persistent and longstanding persistent AF undergoing RFA. The 
duration of persistent AF also has a negative impact on AF ablation success. These findings, 
along with the results from prior studies, suggest that PVI success remains difficult to predict, 
but the longer duration of AF and larger indexed LAV are strongly associated with recurrence 
and should be incorporated into the recurrence stratificationin patients with persistent and 
longstanding persistent AF. 
 
2. In patients with AF recurring after catheter ablation, the time to recurrence is a significant 
predictor of subsequent clinical outcome. Patients with later recurrences (1) are more likely to 
have sporadic AF episodes, (2) can be better managed with AADs, and (3) have better results 
after repeat ablation. 
 
3. For the electrophysiologist treating operated patients with AT, it is very important to 
review surgical records and clarify the specific atriotomy used, since different approaches 
result in different AT mechanisms. Modification of the surgical technique might be effective 
against the future occurrence of AT in these patients. For example, avoiding RA incision by 
using direct LA atriotomy instead of the transseptal approach has been shown to be associated 
with less frequent occurrence of AT.65 
51 
 
 
References 
1. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, 
Puu M, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with 
and without left ventricular systolic dysfunction: Results from the Candesartan in 
Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) 
program. J Am Coll Cardiol 2006; 47:1997–2004. 
2. M Allessie, J Ausma, U Schotten, Electrical, contractile and structural remodeling 
during atrial fibrillation, Cardiovascular Research 54 (2002) 230–246, Review 
3. Oral H, Pappone C, Chugh A, Good E, Bogun F, Pelosi F Jr., Bates ER, et al. 
Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 
2006; 354:934–941. 
4. Hässaguerre M, Jäis P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, et 
al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the 
pulmonary veins. N Engl J Med 1998; 339:659–666. 
5. Riccardo Cappato, Hugh Calkins et al, Updated Worldwide Survey on the Methods, 
Efficacy, and Safety of Catheter Ablation for Human Atrial Fibrillation, Circ 
Arrhythm Electrophysiol. 2010;3:32-38. 
6. Weerasooya R, Khairy P, Litaien J, et al. Catheter ablation for atrial fibrillation. Are 
results maintained at 5 years of follow up? J Am Coll Cardiol 2011;57: 160–166. 
7. Tzou WS, Marchlinski FE, Zado ES, et al. Long-term outcome after successful 
catheter ablation of atrial fibrillation. Circ Arrhythm Electrophysiol 2010;3: 237–242. 
8. To AC, Flamm SD, Marwick TH, Klein AL. Clinical utility of multimodality LA 
imaging: assessment of size, function, and structure. JACC Cardiovasc Imaging. 2011 
Jul;4 (7):788-98. 
9. Kim SJ, Choisy SC, Barman P, Zhang H, Hancox JC, Jones SA, James AF. Atrial 
remodeling and the substrate for atrial fibrillation in rat hearts with elevated afterload. 
Circ Arrhythm Electrophysiol. 2011 Oct; 4 (5):761-9 
10. Casaclang-Verzosa G, Gersh BJ, Tsang TS. Structural and functional remodeling of 
the left atrium: clinical and therapeutic implications for atrial fibrillation. J Am Coll 
Cardiol.2008 Jan 1; 51 (1):1-11.  
52 
 
11. den Uijl DW, Delgado V, Tops LF, Ng AC, Boersma E, Trines SA, Zeppenfeld K, et 
al. Natriuretic peptide levels predict recurrence of atrial fibrillation after 
radiofrequency catheter ablation. Am Heart J 2011; 161:197–203. 
12. Li C, Ding X, Zhang J, Zhou C, Chen Y, Rao L. Does the E/e’ index predict the 
maintenance of sinus rhythm after catheter ablation of atrial fibrillation? 
Echocardiography 2010; 27:630–636. 
13. Shin SH, Park MY, Oh WJ, Hong SJ, Pak HN, Song WH, Lim DS, et al. Left atrial 
volume is a predictor of atrial fibrillation recurrence after catheter ablation. J Am Soc 
Echocardiogr 2008; 21:697–702. 
14. von Bary C, Dornia C, Eissnert C, Nedios S, Roser M, Hamer OW, Gerds-Li JH, et al. 
Predictive value of left atrial volumemeasured by non-invasive cardiac imaging in the 
treatment of paroxysmal atrial fibrillation. J Interv Card Electrophysiol 2012; 34:181–
188. 
15. Caputo M, Urselli R, Capati E, Navarri R, Sinesi L, Furiozzi F, Ballo P, et al. 
Usefulness of left ventricular diastolic dysfunction assessed by pulsed tissue Doppler 
imaging as a predictor of atrial fibrillation recurrence after successful electrical 
cardioversion. Am J Cardiol 2011; 108:698–704. 
16. M. R. Franz, P. L. Karasik, C. Li, J. Moubarak, M. Chavez, Electrical Remodeling of 
the Human Atrium: Similar Effects in Patients With Chronic Atrial Fibrillation and 
Atrial Flutter JACC 1997:1785–92 
17. Hammon, J. W. Extracorporeal circulation: Perfusion system. In L. H. Cohn (Ed.), 
Cardiac surgery in the adult (2008, pp. 350–370). New York: McGraw-Hill.  
18. Anné, W. van Rensburg, H., Adams, J., Ector, H., Van de Werf, F., & Heidbüchel, H. 
Ablation of post-surgical intra-atrial reentrant tachycardia. Predilection target sites and 
mapping approach. European Heart Journal, 2002, 23 (20), 1609–1616. 
19. Nakagawa, H., Shah, N., Matsudaira, K., Overholt, E., Chandrasekaran, K., Beckman, 
K. J., Spector, P., et al. Characterization of reentrant circuit in macroreentrant right 
atrial tachycardia after surgical repair of congenital heart disease: Isolated channels J 
Interv Card Electrophysiol between scars allow "focal" ablation. Circulation, 2001, 
103, 699–709. 
20. Love, B. A., Collins, K. K.,Walsh, E. P., Triedman, J. K. Electroanatomic 
characterization of conduction barriers in sinus/atrially paced rhythm and association 
with intra-atrial reentrant tachycardia circuits following congenital heart disease 
surgery. Journal of Cardiovascular Electrophysiology, 2001, 12(1), 17–25. 
53 
 
21. Shah, D., Jaïs, P., Haïssaguerre, M. Electrophysiological evaluation and ablation of 
atypical right atrial flutter. Cardiac Electrophysiology Review, 2002,6(4), 365–370. 
22. de Groot, N. M., Zeppenfeld, K., Wijffels, M. C., Chan, W. K., Blom, N. A., van der 
Wall, E. E., Schalij, M. J. Ablation of focal atrial arrhythmia in patients with 
congenital heart defects after surgery: Role of circumscribed areas with heterogeneous 
conduction. Heart Rhythm, 2006, 3, 526–535. 
23. Aktas, M. K., Khan, M. N., Di Biase, L., Elayi, C., Martin, D., Saliba, W., Cummings, 
J., Schweikert, R., Natale, A. Higher rate of recurrent atrial flutter and atrial 
fibrillation following atrial flutter ablation after cardiac surgery. Journal of  
cardiovascular Electrophysiology, 2010, 21(7), 760–765. 
24. Chan, D. P., Van Hare, G. F., Mackall, J. A., Carlson, M. D., Waldo, A. L. Importance 
of atrial flutter isthmus in postoperative intra-atrial reentrant tachycardia. Circulation, 
2000, 102(11), 1283–1289. 
25. Verma, A., Marrouche, N. F., Seshadri, N., Schweikert, R. A., Bhargava, M., 
Burkhardt, J. D., Kilicaslan, F., et al. Importance of ablating all potential right atrial 
flutter circuits in postcardiac surgery patients. Journal of the American College of 
Cardiology, 2004, 44 (2), 409–414. 
26. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, et al. 
2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation 
of atrial fibrillation: Recommendations for patient selection, procedural techniques, 
patient management and follow-up, definitions, endpoints, and research trial design: a 
report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical 
Ablation of Atrial Fibrillation. Developed in partnership with the European Heart 
Rhythm Association (EHRA), a registered branch of the European Society of 
Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in 
collaboration with the American College of Cardiology (ACC), American Heart 
Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society 
of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American 
College of Cardiology Foundation, the American Heart Association, the European 
Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of 
Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm 
Society. Heart Rhythm 2012; 9:632–696, e621. 
54 
 
27. Leong-Sit P, Zado E, Callans DJ, Garcia F, Lin D, Dixit S, Bala R, et al. Efficacy and 
risk of atrial fibrillation ablation before 45 years of age. Circ Arrhythm Electrophysiol 
2010; 3:452–457. 
28. Dixit S, Marchlinski FE, Lin D, Callans DJ, Bala R, Riley MP, Garcia FC, et al. 
Randomized ablation strategies for the treatment of persistent atrial fibrillation: 
RASTA study. Circ Arrhythm Electrophysiol 2012; 5:287–294. 
29. Gerstenfeld EP, Dixit S, Callans D, Rho R, Rajawat Y, Zado E, Marchlinski FE. 
Utility of exit block for identifying electrical isolation of the pulmonary veins. J 
Cardiovasc Electrophysiol 2002; 13:971–979. 
30. Gerstenfeld EP, Sauer W, Callans DJ, et al. Predictors of success after selective 
pulmonary vein isolation of arrhythmogenic pulmonary veins for treatment of atrial 
fibrillation. Heart Rhythm 2006;3:165–170. 
31. Roux J-F, Zado E, Callans J, et al. Antiarrhythmics after ablation of atrial fibrillation 
(5A Study). Circulation 2009;120:1036–1040. 
32. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard 
MH, et al. Recommendations for chamber quantification: A report from the American 
Society of Echocardio-graphy’s Guidelines and Standards Committee and the 
Chamber Quantification Writing Group, developed in conjunction with the European 
Association of Echocardiography, a branch of the European Society of Cardiology. J 
Am Soc Echocardiogr 2005; 18:1440–1463. 
33. Marchese P, Malavasi V, Rossi L, Nikolskaya N, Donne GD, Becirovic M, Colantoni 
A, et al. Indexed left atrial volume is superior to left atrial diameter in predicting 
nonvalvular atrial fibrillation recurrence after successful cardioversion: A prospective 
study. Echocardiography 2012; 29:276–284. 
34. Marchese P, Bursi F, Delle Donne G, Malavasi V, Casali E, Barbieri A, Melandri F, et 
al. Indexed left atrial volume predicts the recurrence of non-valvular atrial fibrillation 
after successful cardioversion. Eur J Echocardiogr 2011; 12:214–221. 
35. Abecasis J, Dourado R, Ferreira A, Saraiva C, Cavaco D, Santos KR, Morgado FB, et 
al. Left atrial volume calculated by multidetector computed tomography may predict 
successful pulmonary vein isolation in catheter ablation of atrial fibrillation. Europace 
2009; 11:1289–1294. 
36. Hof I, Chilukuri K, Arbab-Zadeh A, Scherr D, Dalal D, Nazarian S, Henrikson C, et 
al. Does left atrial volume and pulmonary venous anatomy predict the outcome of 
55 
 
catheter ablation of atrial fibrillation? J Cardiovasc Electrophysiol 2009; 20:1005–
1010. 
37. Lee SH, Tai CT, Hsieh MH, Tsai CF, Lin YK, Tsao HM, Yu WC, et al. Predictors of 
early and late recurrence of atrial fibrillation after catheter ablation of paroxysmal 
atrial fibrillation. J Interv Card Electrophysiol 2004; 10:221–226. 
38. Lin D, Frankel DS, Zado ES, Gerstenfeld E, Dixit S, Callans DJ, Riley M, et al. 
Pulmonary vein antral isolation and nonpulmonary vein trigger ablation without 
additional substrate modification for treating longstanding persistent atrial fibrillation. 
J Cardiovasc Electrophysiol 2012; 23:806–813. 
39. Kataoka T, Hamasaki S, Inoue K, Yuasa T, Tomita K, Ishida S, Ogawa M, et al. Left 
atrium volume index and pathological features of left atrial appendage as a predictor 
of failure in postoperative sinus conversion. J Cardiol 2010; 55:274–282. 
40. Burstein B, Nattel S. Atrial fibrosis: Mechanisms and clinical relevance in atrial 
fibrillation. J Am Coll Cardiol 2008; 51:802–809. 
41. Fatema K, Barnes ME, Bailey KR, Abhayaratna WP, Cha S, Seward JB, Tsang TS. 
Minimum vs. maximum left atrial volume for prediction of first atrial fibrillation or 
flutter in an elderly cohort: A prospective study. Eur J Echocardiogr 2009; 10:282–
286. 
42. Hsieh MH, Tai CT, Tsai CF, et al. Clinical outcome of very late recurrence of atrial 
fibrillation after catheter ablation of paroxysmal atrial fibrillation. J Cardiovasc 
Electrophysiol 2003;14:598–601. 
43. Shah AN, Mittal S, Sichrovsky TC, et al. Long-term outcome following successful 
pulmonary vein isolation: pattern and prediction of very late recurrence. J. Cardiovasc 
Electrophysiol 2008;19:661–667. 
44. Hsieh MH, Tai CT, Lee SH, et al. The different mechanisms between late and very 
late recurrences of atrial fibrillation in patients undergoing a repeated catheter 
ablation. J Cardiovasc Electrophysiol 2006;17:231–235. 
45. Themistoclakis S, Schweikert R, Saliba W, et al. Clinical predictors and relationship 
between early and late atrial tachyarrhythmias after pulmonary vein antrum isolation. 
Heart Rhythm 2008;5:679–685. 
46. Mainigi SK, Sauer WH, Cooper JM, et al. Incidence and predictors of very late 
recurrence of atrial fibrillation after ablation. J. Cardiovasc Electrophysiol 
2007;18:69–74. 
56 
 
47. Verma A, Kilicaslan F, Pissano E, et al. Response of atrial fibrillation to pulmonary 
vein antrum isolation is directly related to resumption and delay of pulmonary vein 
conduction. Circulation 2005;112:627–635. 
48. Lukac, P., Pedersen, A. K., Mortensen, P. T., Jensen, H. K., Hjortdal, V., Hansen, P. S. 
Ablation of atrial tachycardiaafter surgery for congenital and acquired heart disease 
using an electroanatomic mapping system: Which circuits to expect in which 
substrate? Heart Rhythm, 2005, 2(1), 64–72. 
49. Tomita, Y., Matsuo, K., Sahadevan, J., Khrestian, C. M., Waldo, A. L. Role of 
functional block extension in lesion-related atrial flutter. Circulation, 2001, 103(7), 
1025–1030. 
50. Bui, H. M., Khrestian, C. M., Ryu, K., Sahadevan, J., Waldo, A. L. Fixed intercaval 
block in the setting of atrial fibrillationpromotes the development of atrial flutter. 
Heart Rhythm, 2008, 5(12),1745–1752. 
51. Akar, J. G., Kok, L. C., Haines, D. E., DiMarco, J. P., Mounsey, J. P. Coexistence of 
type I atrial flutter and intra-atrial reentrant tachycardia in patients with surgically 
corrected congenital heart disease. Journal of the American College of Cardiology, 
2001, 38(2), 377–384. 
52. Hebe, J., Hansen, P., Ouyang, F., Volkmer, M., Kuck, K. H. Radiofrequency catheter 
ablation of tachycardia in patients with congenital heart disease. Pediatric Cardiology, 
2000, 21(6), 557–575. 
53. Markowitz, S. M., Brodman, R. F., Stein, K. M., Mittal, S., Slotwiner, D. J., Iwai, S., 
Das, M. K., et al. Lesional tachycardias related to mitral valve surgery. Journal of the 
American College of Cardiology, 2002, 39(12), 1973–1983. 
54. Waldo, A. L. Mechanisms of atrial flutter and atrial fibrillation: Distinct entities or two 
sides of a coin? Cardiovascular Research, 2002, 54(2), 217–229. 
55. Mori, S. S., Fujii, G. G., Ishida, H. H., Tomari, S. S., Matsuura, A. A., Yoshida, K. K. 
Atrial flutter after coronary arterybypass grafting: Proposed mechanism as illuminated 
by independent predictors. Annals of Thoracic and Cardiovascular Surgery, 2003, 9, 
50–56. 
56. Magnin-Poull, I., De Chillou, C., Miljoen, H., Andronache, M., Aliot, E. Mechanisms 
of right atrial tachycardia occurring late after surgical closure of atrial septal defects. 
Journal of Cardiovascular Electrophysiology, 2005, 16(7), 681–687. 
57 
 
57. Lukac, P., Hjortdal, V., Pedersen, A. K., Jensen, H. K., Mortensen, P. T., Hansen, P. S. 
The superior transseptal surgicalapproach to mitral valve creates slow conduction. 
Pacing and Clinical Electrophysiology, 2006, 29(7), 719–726. 
58. Roberts-Thomson, K. C., Kalman, J. M. Right septal macroreentrant tachycardia late 
after mitral valve repair: Importance of surgical access approach. Heart Rhythm, 2007, 
4(1), 32–36. 
59. Pap, R., Makai, A., Sághy, L. Post-incisional right atrial tachycardia eliminated by a 
single radiofrequency lesion. Journal of Interventional Cardiac Electrophysiology, 
2007, 19(2), 73–76. 
60. Snowdon, R. L., Balasubramaniam, R., Teh, A. W., Haqqani, H. M., Medi, C., Rosso, 
R., Vohra, J. K., Kistler, P. M., Morton, J. B.,Sparks, P. B., Kalman, J. M. Linear 
ablation of right atrial free wall flutter: Demonstration of bidirectional conduction 
block as an endpoint associated with long-term success. Journal of Cardiovascular 
Electrophysiology, 2010, 21(5), 526–531. 
61. Jaïs, P., Shah, D. C., Haïssaguerre, M., Hocini, M., Peng, J. T., Takahashi, A., 
Garrigue, S., et al. Mapping and ablation of left atrial flutters. Circulation, 2000, 
101(25), 2928–2934. 
62. Ouyang, F., Ernst, S., Vogtmann, T., Goya, M., Volkmer, M., Schaumann, A., Bänsch, 
D., et al. Characterization of reentrant circuits in left atrial macroreentrant tachycardia: 
Critical isthmus block can prevent atrial tachycardia recurrence. irculation, 2002, 
105(16), 1934–1942. 
63. de Groot, N. M., Atary, J. Z., Blom, N. A., Schalij, M. J. Long-term outcome after 
ablative therapy of postoperative atrialtachyarrhythmia in patients with congenital 
heart disease and characteristics of atrial tachyarrhythmia recurrences. Circulation.  
Arrhythmia and Electrophysiology, 2010, 3(2), 148–154. 
64. Chen, S. A., Tai, C. T., Chiang, C. E., Ding, Y. A., Chang, M. S. Focal atrial 
tachycardia: Reanalysis of the clinical andelectrophysiologic characteristics and 
prediction of successful radiofrequency ablation. Journal of Cardiovascular 
Electrophysiology, 1998, 9(4), 355–365. 
65. Lukac, P., Hjortdal, V. E., Pedersen, A. K., Mortensen, P. T., Jensen, H. K., Hansen, 
P. S. Atrial incision affects the incidence of atrial tachycardia after mitral valve 
surgery. The Annals of Thoracic Surgery, 2006, 81(2), 509–513.  
58 
 
Acknowledgement 
First of all, I would like to thank my supervisor, László Sághy, for the patient guidance, 
encouragement and advice he has provided throughout my time as his PhD fellow.  
I’m especially grateful to my supervisors in Philadelphia, Dr. Yuchi Han, Dr. David J. Callans 
and Dr. Francis E. Marchlinski who have provided me with the opportunity to perform my 
work in their departments and for their support and cooperation in my scientific work. 
I greatly acknowledge the continous encouragement of Professor Tamás Forster who provided 
me with the opportunity to begin my work at the 2nd Department of Internal Medicine and 
Cardiology Center. 
I would like to thank Dr. Larraitz Gaztanaga, who as a good friend was always willing to help 
and give her best suggestions. 
I’m thankful to all collegues, all nurses and secretaries in the EP Lab for their support. 
Last, but not least, I’m most indebted to my family for their understanding, support, patience 
and love.  
 
